268 related articles for article (PubMed ID: 15990594)
1. Lipoprotein-associated phospholipase A2 as a target of therapy.
Macphee CH; Nelson JJ; Zalewski A
Curr Opin Lipidol; 2005 Aug; 16(4):442-6. PubMed ID: 15990594
[TBL] [Abstract][Full Text] [Related]
2. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.
Zalewski A; Macphee C
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):923-31. PubMed ID: 15731492
[TBL] [Abstract][Full Text] [Related]
3. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Tselepis AF; Rizzo M; Goudevenos IA
Curr Pharm Des; 2011 Nov; 17(33):3656-61. PubMed ID: 22074435
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.
Kolodgie FD; Burke AP; Skorija KS; Ladich E; Kutys R; Makuria AT; Virmani R
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2523-9. PubMed ID: 16960105
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Wilensky RL; Macphee CH
Curr Opin Lipidol; 2009 Oct; 20(5):415-20. PubMed ID: 19667981
[TBL] [Abstract][Full Text] [Related]
7. Lp-PLA2: a new kid on the block.
Zalewski A; Nelson JJ; Hegg L; Macphee C
Clin Chem; 2006 Sep; 52(9):1645-50. PubMed ID: 16873290
[TBL] [Abstract][Full Text] [Related]
8. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.
Tellis CC; Tselepis AD
Biochim Biophys Acta; 2009 May; 1791(5):327-38. PubMed ID: 19272461
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.
MacPhee CH; Moores KE; Boyd HF; Dhanak D; Ife RJ; Leach CA; Leake DS; Milliner KJ; Patterson RA; Suckling KE; Tew DG; Hickey DM
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):479-87. PubMed ID: 10024526
[TBL] [Abstract][Full Text] [Related]
10. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Sudhir K
J Clin Endocrinol Metab; 2005 May; 90(5):3100-5. PubMed ID: 15713711
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.
Caslake MJ; Packard CJ
Curr Opin Lipidol; 2003 Aug; 14(4):347-52. PubMed ID: 12865731
[TBL] [Abstract][Full Text] [Related]
12. Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients.
Ishihara M; Iwasaki T; Nagano M; Ishii J; Takano M; Kujiraoka T; Tsuji M; Hattori H; Emi M
J Hum Genet; 2004; 49(6):302-307. PubMed ID: 15148590
[TBL] [Abstract][Full Text] [Related]
13. Community-based statins and advanced carotid plaque: Role of CD163 positive macrophages in lipoprotein-associated phospholipase A
Otsuka F; Zhao X; Trout HH; Qiao Y; Wasserman BA; Nakano M; Macphee CH; Brandt M; Krug-Gourley S; Guo L; Ladich ER; Cheng Q; Davis HR; Finn AV; Virmani R; Kolodgie FD
Atherosclerosis; 2017 Dec; 267():78-89. PubMed ID: 29101839
[TBL] [Abstract][Full Text] [Related]
14. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation.
Gonçalves I; Edsfeldt A; Ko NY; Grufman H; Berg K; Björkbacka H; Nitulescu M; Persson A; Nilsson M; Prehn C; Adamski J; Nilsson J
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1505-12. PubMed ID: 22499993
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target.
Macphee C; Benson GM; Shi Y; Zalewski A
Expert Opin Investig Drugs; 2005 Jun; 14(6):671-9. PubMed ID: 16004595
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro.
Turunen P; Jalkanen J; Heikura T; Puhakka H; Karppi J; Nyyssönen K; Ylä-Herttuala S
J Lipid Res; 2004 Sep; 45(9):1633-9. PubMed ID: 15231855
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Carlquist JF; Muhlestein JB; Anderson JL
Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
[TBL] [Abstract][Full Text] [Related]
18. [Lipoprotein associated phospholipase A2].
Rubinstein A; Izkhakov E
Harefuah; 2011 Feb; 150(2):136-40, 205. PubMed ID: 22164942
[TBL] [Abstract][Full Text] [Related]
19. Lp-PLA2: an emerging biomarker of coronary heart disease.
Dada N; Kim NW; Wolfert RL
Expert Rev Mol Diagn; 2002 Jan; 2(1):17-22. PubMed ID: 11963798
[TBL] [Abstract][Full Text] [Related]
20. [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques].
Bonnefont-Rousselot D
Ann Pharm Fr; 2016 May; 74(3):190-7. PubMed ID: 26499399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
